Thrombocytopenia after Implantation of the Perceval, Intuity, and Sapien Aortic Valve Prostheses

Abstract

Background An increased incidence of thrombocytopenia was reported after implantation of the LivaNova Perceval and the Edwards Sapien aortic valve bioprostheses. Aim of this study is to assess the perioperative platelet count and bleeding complications in three different types of aortic valve bioprostheses intended for high-risk patients, the sutureless LivaNova Perceval, the rapid deployment Edwards Intuity, and the transcatheter Edwards Sapien.

Methods We performed a retrospective analysis of the perioperative data of patients receiving the Perceval, Intuity, and Sapien aortic valve bioprosthesis. The platelet count was collected preoperatively, at nadir postoperatively, and at discharge. The bioprostheses were compared for between-group differences in platelet count and postoperative bleeding complications.

Results Overall, 37 patients received the Perceval, 42 the Intuity, and 58 the Sapien bioprosthesis. There was no significant between-group difference in the preoperative platelet count [Perceval 203(178–246)G/l, Intuity 214(190–232)G/l, Sapien 201(178–275)G/l, p = 0.800]. There was a significant between-group difference in the postoperative platelet count, both at nadir value [Perceval 57(37–80)G/l, Intuity 91(73–109)G/l, Sapien 126(105–170)G/l, p < 0.0001] and at discharge [Perceval 150(83–257)G/l, Intuity 239(200–343)G/l, Sapien 232(179–284)G/l, p = 0.001]. There was no significant between-group difference regarding red blood cell transfusions (p = 0.242), platelet transfusions (p = 0.656), and rethoracotomy for bleeding (p = 0.847).

Conclusion We found a significant platelet count reduction in all three bioprostheses which was more marked in the Perceval group. The platelet count reduction was transient and fully recovered in the Intuity and Sapien groups, whereas the Perceval group showed only a partial platelet count recovery. However, bleeding complications were not different between the three bioprostheses.

Keywords

aortic valve bioprosthesis - transapical TAVI - outcomes (includes mortality and morbidity)

Publication History

Received: 12 May 2022

Accepted: 06 September 2022

Article published online:
03 December 2022

• References

• 1 Gersak B, Fischlein T, Folliguet TA. et al. Sutureless, rapid deployment valves and stented bioprosthesis in aortic valve replacement: recommendations of an International Expert Consensus Panel. Eur J Cardiothorac Surg 2016; 49 (03) 709-718
• 2 Werner N, Zahn R, Beckmann A. et al; GARY Executive Board. Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve implantation for severe symptomatic aortic valve stenosis. Circulation 2018; 138 (23) 2611-2623
• 3 Thomas M, Schymik G, Walther T. et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: A European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010; 122 (01) 62-69
• 4 Lorusso R, Jiritano F, Roselli E. et al; PERSIST-AVR Investigators. Perioperative platelet reduction after sutureless or stented valve implantation: results from the PERSIST-AVR controlled randomized trial. Eur J Cardiothorac Surg 2021; 60 (06) 1359-1365
• 5 Sena A, Ferreira R, Nobre M. et al. Platelet count drop after rapid deployment aortic valve implantation. Rev Port Cir Cardiotorac Vasc 2020; 27 (02) 91-96
• 6 Stegmeier P, Schlömicher M, Stiegler H, Strauch JT, Bechtel JFM. Thrombocytopenia after implantation of the Perceval S aortic bioprosthesis. J Thorac Cardiovasc Surg 2020; 160 (01) 61-68.e8
• 7 Powell R, Pelletier MP, Chu MWA, Bouchard D, Melvin KN, Adams C. The perceval sutureless aortic valve: review of outcomes, complications, and future direction. Innovations (Phila) 2017; 12 (03) 155-173
• 8 Stanger O, Grabherr M, Gahl B. et al. Thrombocytopaenia after aortic valve replacement with stented, stentless and sutureless bioprostheses. Eur J Cardiothorac Surg 2017; 51 (02) 340-346
• 9 Jiritano F, Cristodoro L, Malta E, Mastroroberto P. Thrombocytopenia after sutureless aortic valve implantation: comparison between Intuity and Perceval bioprostheses. J Thorac Cardiovasc Surg 2016; 152 (06) 1631-1633
• 10 Sánchez E, Corrales J-A, Fantidis P. et al. Thrombocytopenia after aortic valve replacement with Perceval S sutureless bioprosthesis. J Heart Valve Dis 2016; 25 (01) 75-81
• 11 König KC, Wahlers T, Scherner M, Wippermann J. Sutureless Perceval aortic valve in comparison with the stented Carpentier-Edwards Perimount aortic valve. J Heart Valve Dis 2014; 23 (02) 253-258
• 12 Flameng W, Herregods M-C, Hermans H. et al. Effect of sutureless implantation of the Perceval S aortic valve bioprosthesis on intraoperative and early postoperative outcomes. J Thorac Cardiovasc Surg 2011; 142 (06) 1453-1457
• 13 Mujtaba SS, Ledingham S, Shah AR, Schueler S, Clark S, Pillay T. Thrombocytopenia after aortic valve replacement: comparison between sutureless Perceval S Valve and Perimount Magna Ease Bioprosthesis. Rev Bras Cir Cardiovasc 2018; 33 (02) 169-175
• 14 Mitrosz M, Kazimierczyk R, Sobkowicz B. et al. The causes of thrombocytopenia after transcatheter aortic valve implantation. Thromb Res 2017; 156: 39-44
• 15 Flaherty MP, Mohsen A, Moore IV JB. et al. Predictors and clinical impact of pre-existing and acquired thrombocytopenia following transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2015; 85 (01) 118-129
• 16 McCabe JM, Huang P-H, Riedl LA. et al. Incidence and implications of idiopathic thrombocytopenia following transcatheter aortic valve replacement with the Edwards Sapien(©) valves: a single center experience. Catheter Cardiovasc Interv 2014; 83 (04) 633-641